Progeni predicts candidate melanoma and colorectal-cancer targets validated in cell models
Progeni combines a probabilistic knowledge graph with graph neural networks to rank disease-associated molecular targets. The authors selected six candidates lacking literature support and reported that knockdown of HSP90AB1 and MME reduced proliferation in a murine melanoma line, while knockdown of ADCY5, ADRA2A and EEF2 reduced proliferation in a murine colorectal-cancer line.
Technology: Progeni probabilistic knowledge graph and graph neural network
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The authors selected six candidates lacking literature support and reported that knockdown of HSP90AB1 and MME reduced proliferation in a murine melanoma line, while knockdown of ADCY5, ADRA2A and EEF2 reduced proliferation in a murine colorectal-cancer line.
- Still unknown: The functional validations were in B16F10 and MC38 murine cell lines, not human tumor samples or clinical settings. The paper evaluates a model and validates selected candidates; it does not establish these as clinically effective therapeutic targets.
- AI role: The graph neural network ranked new target hypotheses from heterogeneous biological networks and literature co-occurrence evidence. Researchers then tested selected predictions by shRNA knockdown in representative murine cancer cell lines.
Evidence sources: https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1011945
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 81 of works of the same type, year and subfield (OpenAlex work metrics, 11 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.